Celgene's Multiple Myeloma Triplet Succeeds in Key Phase III Trial Post author:Sam Post published:February 5, 2018 Post category:BioPharma The international clinical study, OPTIMISMM, achieved its primary endpoint. Source: BioSpace You Might Also Like What Brent Saunders Thinks About a Possible Allergan Breakup October 19, 2017 Why Gilead Could Take Out Juno But Face Major Competition From This Biotech Giant August 29, 2017 Trump's CDC Director Resigns Over Pharma, Tobacco Investments January 31, 2018
